Replies to post #100974 on Biotech Values

[DewDiligence]

IDIX—[CEO] J.P. [Sommadossi], if I understood him correctly, anticipates that IDIX's first pivotal trial will include 184 + 320 + peg/riba against telaprevir + peg/riba.

It’s notable that JP said Telaprevir, specifically, rather than “a first-generation PI.” JP presumably read MRK’s PR in #msg-52949888 before speaking at the BMO conference today :- )